Treatment-Related AML Rises in Non-Hodgkin's Lymphoma
The risks of chemotherapy-related acute myeloid leukemia have changed significantly over the last 30 years, increasing in people treated for non-Hodgkin's lymphoma and decreasing in people treated for... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - February 26, 2013 Category: Cancer & Oncology Source Type: news

Bendamustine (Levact®) Plus Rituximab More Effective Than CHOP-R In Treating Patients With Indolent Non-Hodgkin Lymphoma And Mantle Cell Lymphoma
Treatment with bendamustine plus rituximab (B-R) doubles progression free survival (PFS) compared with current standard of care CHOP-R (69.5 versus 31.2 months; p Results from the StiL NHL-1 study published in The Lancet this week show that a first-line treatment regimen of bendamustine plus rituximab (B-R) doubles progression-free survival (PFS) compared with the most often used treatment CHOP plus rituximab (CHOP-R), in newly diagnosed patients with indolent non-Hodgkin lymphoma (iNHL) and mantle cell lymphoma (MCL).1 Median PFS for patients treated with B-R was 69... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 22, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

Bendamustine data published in The Lancet
Results from the StiL NHL-1 study published in The Lancet show that a first-line treatment regimen of bendamustine plus rituximab (B-R) doubles progression-free survival (PFS) compared with the most often used treatment CHOP plus rituximab (CHOP-R), in newly diagnosed patients with indolent non-Hodgkin lymphoma (iNHL) and mantle cell lymphoma (MCL). (Source: Pharmacy Europe)
Source: Pharmacy Europe - February 22, 2013 Category: Drugs & Pharmacology Source Type: news

Diffuse Large B-Cell Non-Hodgkin Lymphoma in the Very Elderly: Challenges and Solutions
In this review, we critically analyze clinical trials that were specifically designed for the very elderly, and we discuss the challenges encountered by investigators who are conducting studies in this patient population. We conclude by proposing an algorithm to help clinicians determine the optimal therapeutic strategy for treatment of DLBCL in very elderly patients. (Source: Cancer Network)
Source: Cancer Network - February 15, 2013 Category: Cancer & Oncology Source Type: news

After cancer, my real fight began
In January of 2011, at 25, I was diagnosed with non-Hodgkin's lymphoma. I went through four months of chemotherapy and eight weeks of radiation. (Source: CNN.com - Health)
Source: CNN.com - Health - January 31, 2013 Category: Consumer Health News Source Type: news

Cancer death rates are a third higher in men
The fact that men are more likely than women to both develop and die from cancer has been covered by most of the media today. The news is based on a report highlighting the excess cancer burden in men (both in terms of cases and deaths), and was produced by Cancer Research UK, the Men’s Health Forum and the National Cancer Intelligence Network. The results of the report were widely and accurately reported in the media. The report found that men are at significantly greater risk of both developing and dying from cancer, and the difference in risk increased further when breast and sex-specific cancers, for examp...
Source: NHS News Feed - January 29, 2013 Category: Consumer Health News Tags: Cancer QA articles Source Type: news

Non-Hodgkin Lymphoma
Prognostic Factors and Targetsseries:Cancer Drug Discovery and DevelopmentRecent developments in the therapy of non-Hodgkin lymphoma have improved response and survival rates in patients with these conditions. This book is focused on the biology, prognostic factors and novel targets of non-Hodgkin lymphoma. We believe that understanding the pathophysiology of non-Hodgkin lymphoma provides a mean to improve its risk-stratification and treatment. This book is intended ... (Source: Springer Biomedical Sciences titles)
Source: Springer Biomedical Sciences titles - January 26, 2013 Category: Biomedical Science Tags: Cancer Research Source Type: news

Five-Minute' Blood Cancer Injection Cuts Treatment Time By Two Hours
A new injection for blood cancer patients trialled at Southampton's teaching hospitals can deliver a two-hour dose of drugs in around five minutes. Patients diagnosed with follicular non-Hodgkin lymphoma (NHL), a disease that attacks one specific type of infection-fighting cell, previously had rituximab administered via an intravenous drip... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 24, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

Patient Survival In Non-Hodgkins Lymphoma Predicted By Epigenomic Abnormalities
Think of the epigenome like a giant musical mixing board, turning up or down the expression of various genes. A University of Colorado Cancer Center study published in the journal PLOS Genetics shows that in cancer, not only can genes themselves go bad, but abnormal changes in the epigenetic mixing board can unfortunately change the expression of these genes. Researchers hope to play the role of sound engineers, controlling these harmful epigenomic changes to turn down cancer itself or perhaps sensitize cancers to existing drugs... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 13, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

PCR-Based Analysis of Rearranged Immunoglobulin or T-Cell Receptor Genes by GeneScan Analysis or Heteroduplex Analysis for Clonality Assessment in Lymphoma Diagnostics
The assessment of the presence of clonal lymphoproliferations via polymerase chain reaction (PCR)-based analysis of rearranged immunoglobulin (Ig) or T-cell receptor (TCR) genes is a valuable technique in the diagnosis of suspect lymphoproliferative disorders. Furthermore this technique is more and more used to evaluate dissemination of non-Hodgkin lymphoma and/or the presence of (minimal) residual disease. In this chapter we describe an integrated approach to assess clonality via analysis of Ig heavy chain (IGH), Ig kappa (IGK), TCR beta (TCRB), and TCR gamma (TCRG) gene rearrangements. The described PCR protocol is based...
Source: Springer protocols feed by Cancer Research - January 11, 2013 Category: Cancer & Oncology Source Type: news

Epigenomic abnormalities predict patient survival in non-Hodgkins lymphoma
"Not only do we see more abnormal methylation in non-Hodgkin lymphoma patients than in healthy B-cell populations, but there are three distinct subtypes of the disease in the clinic, each more aggressive than the next. These three clinical trajectories of non-Hodgkins lymphoma were distinctly marked by their levels of abnormal methylation," says a CU Cancer Center investigator. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 11, 2013 Category: Science Source Type: news

Epigenomic abnormalities predict patient survival in non-Hodgkins lymphoma
(University of Colorado Denver) "Not only do we see more abnormal methylation in non-Hodgkin lymphoma patients than in healthy B-cell populations, but there are three distinct subtypes of the disease in the clinic, each more aggressive than the next. These three clinical trajectories of non-Hodgkins lymphoma were distinctly marked by their levels of abnormal methylation," says a CU Cancer Center investigator. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 10, 2013 Category: Cancer & Oncology Source Type: news

TG Therapeutics commences TGR-1202 Phase I trial
TG Therapeutics has begun first-in-human, Phase I trial of TGR-1202 in patients suffering from hematologic malignancies such as relapsed or refractory Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia and Peripheral T-Cell Lymphoma. (Source: Drug Development Technology)
Source: Drug Development Technology - January 9, 2013 Category: Pharmaceuticals Source Type: news

Unusual Analyst Upgrade & Endorsement for Cell Therapeutics (CTIC)
Cell Therapeutics, Inc. (NASDAQ: CTIC) is a controversial stock in the field of cancer and the company is still aiming for a 2012 debut market launch for its pixantrone drug candidate.  In the last couple of weeks it had reported more positive data and the FDA had earlier this year noted that pixantrone would need a review using a new panel of independent radiologists.  Pixantrone is to be a new treatment for non-Hodgkin Lymphoma.   This morning we saw a very unlikely and very unusual support or endorsement of Cell Therapeutics.  This came from Zacks Investment Research where the outfit was called The B...
Source: BioHealth Investor - October 13, 2011 Category: Pharmaceuticals Authors: 247admin Tags: analyst calls Cancer fda R&D Research CTIC Source Type: news

ADAO Lights a Candle for Workers' Memorial Day
On April 28, the Asbestos Disease and Awareness Organization (ADAO) will recognize Workers' Memorial Day through their Light a Candle program. The program encourages people to light a candle or do so through their website to honor loved ones who are fighting or have lost their fight against asbestos-related diseases. As of April 26 2011, over 11 million candles have been lit in a total of 243 countries. Each year, approximately 125 million workers are regularly exposed to asbestos. Asbestos has been directly linked to the development of malignant mesothelioma, an uncommon and aggressive cancer that attacks the lining of th...
Source: Asbestos and Mesothelioma News - April 26, 2011 Category: Environmental Health Authors: Michael Sedacca Tags: Asbestos Exposure & Bans Source Type: news

Van Andel Institute conducting cancer research in Asia
The Van Andel Research Institute will soon be conducting cancer research in Southeast Asia. It’s being called a ground breaking agreement. The $1.2 million, 3 year deal is funded by the National Cancer Center in Singapore. Scientists would study types of cancer that seem to be more prevalent among certain ethnic groups. The study will compare cancer in Caucasian patients verses cancer in Asian patients. For example, prostate cancer is more prevalent among white people. Liver cancer seems be more prevalent among Asians. WZZM 13 News got a glimpse inside the Van Andel Research Institute, where doctors say they ar...
Source: Kidney Cancer Association - November 1, 2007 Category: Urology & Nephrology Source Type: news

Van Andel Institute conducting cancer research in Asia
The Van Andel Research Institute will soon be conducting cancer research in Southeast Asia. It’s being called a ground breaking agreement. The $1.2 million, 3 year deal is funded by the National Cancer Center in Singapore. Scientists would study types of cancer that seem to be more prevalent among certain ethnic groups. The study will compare cancer in Caucasian patients verses cancer in Asian patients. For example, prostate cancer is more prevalent among white people. Liver cancer seems be more prevalent among Asians. WZZM 13 News got a glimpse inside the Van Andel Research Institute, where doctors say they are maki...
Source: Kidney Cancer Association - November 1, 2007 Category: Urology & Nephrology Source Type: news

NCCN to Present Guidelines in China
JENKINTOWN, Pa., February 21, 2007 — The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 20 of the world’s leading cancer centers, will present the Breast, Colorectal, Gastric, Non-Small Cell Lung and Non-Hodgkin`s Lymphoma (NHL) NCCN Clinical Practice Guidelines in Oncology in Beijing, Shanghai and Guangzhou, China. Over the course of five meetings in March and April, experts from NCCN Member Institutions and leading physicians in China will review and adapt these gui... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - February 21, 2007 Category: Cancer & Oncology Source Type: news

Utilization of Rituximab Therapy in Patients (pts) with Newly Diagnosed Follicular (FL) and Diffuse Large B Cell (DLCL) Non-Hodgkins Lymphoma (NHL) in the United States: An Analysis from the National Comprehensive Cancer Network (NCCN)
[1800] Utilization of Rituximab Therapy in Patients (pts) with Newly Diagnosed Follicular (FL) and Diffuse Large B Cell (DLCL) Non-Hodgkins Lymphoma (NHL) in the United States: An Analysis from the National Comprehensive Cancer Network (NCCN) [abstract]. NHL Outcomes Project [abstract]. American Society of Hematology: Session Type: Poster Session 912-I Jonathan W. Friedberg, Eva Lepisto, Maria Alma Rodriguez, Rebecca Ottensen, Ann S. LaCasce, Auayporn P. Nademanee, Michael Millenson, Myro... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - November 16, 2003 Category: Cancer & Oncology Source Type: news